Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC.
Roussot N, Thibaudin M, Fumet JD, Daumoine S, Hampe L, Rébé C, Limagne E, Lagrange A, Herreros V, Lecuelle J, Mananet H, Ilie A, Rageot D, Boidot R, Goussot V, Comte A, Jacob P, Beltjens F, Bergeron A, Charon-Barra C, Arnould L, Derangère V, Ladoire S, Truntzer C, Ghiringhelli F. Roussot N, et al. Among authors: derangere v. Front Immunol. 2024 Aug 7;15:1437961. doi: 10.3389/fimmu.2024.1437961. eCollection 2024. Front Immunol. 2024. PMID: 39170614 Free PMC article.
Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts.
Lecuelle J, Truntzer C, Basile D, Laghi L, Greco L, Ilie A, Rageot D, Emile JF, Bibeau F, Taïeb J, Derangere V, Lepage C, Ghiringhelli F. Lecuelle J, et al. Among authors: derangere v. EBioMedicine. 2024 Jul;105:105207. doi: 10.1016/j.ebiom.2024.105207. Epub 2024 Jun 15. EBioMedicine. 2024. PMID: 38880067 Free PMC article.
CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Schoumacher C, Derangère V, Gaudillière-Le Dain G, Huppe T, Rageot D, Ilie A, Vienot A, Borg C, Monnien F, Bibeau F, Truntzer C, Ghiringhelli F; CGE-Pancreas investigators. Schoumacher C, et al. Among authors: derangere v. Oncoimmunology. 2023 Dec 21;13(1):2294563. doi: 10.1080/2162402X.2023.2294563. eCollection 2024. Oncoimmunology. 2023. PMID: 38169969 Free PMC article.
Evaluation of immune infiltrate according to the HER2 status in colorectal cancer.
Molimard C, Dor F, Overs A, Monnien F, Gessain G, Kedochim L, D'Angelo F, Abad M, Heberle M, Derangère V, Ghiringhelli F, Vuitton L, Valmary-Degano S, Borg C, Lakkis Z, Bibeau F. Molimard C, et al. Among authors: derangere v. Dig Liver Dis. 2024 May;56(5):853-860. doi: 10.1016/j.dld.2023.09.015. Epub 2023 Oct 14. Dig Liver Dis. 2024. PMID: 37845155 Free article.
Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients.
Mazel B, Bertolone G, Baurand A, Cosset E, Sawka C, Robert M, Gautier E, Lançon A, Réda M, Favier L, Dérangère V, Richard C, Binquet C, Boidot R, Goussot V, Albuisson J, Ghiringhelli F, Faivre L, Nambot S. Mazel B, et al. Among authors: derangere v. Cancer Med. 2023 Sep;12(18):18786-18796. doi: 10.1002/cam4.6498. Epub 2023 Sep 11. Cancer Med. 2023. PMID: 37694493 Free PMC article.
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. Thibaudin M, et al. Among authors: derangere v. Nat Med. 2023 Aug;29(8):2087-2098. doi: 10.1038/s41591-023-02497-z. Epub 2023 Aug 10. Nat Med. 2023. PMID: 37563240 Free PMC article. Clinical Trial.
GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC.
Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M, Dondaine L, Ballot E, Truntzer C, Boidot R, Hermetet F, Derangère V, Bruchard M, Végran F, Chouchane L, Ghiringhelli F, Bettaieb A, Paul C. Mabrouk N, et al. Among authors: derangere v. Cancers (Basel). 2023 Jun 9;15(12):3129. doi: 10.3390/cancers15123129. Cancers (Basel). 2023. PMID: 37370739 Free PMC article.
73 results